Headquartered in Buffalo, New York, 22nd Century Group is a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research.

MOCKSVILLE, N.C.,, June 26, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that is leading the fight against nicotine by offering smokers a choice ...

MOCKSVILLE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a ...

22nd Century Group, Inc. (XXII) is one of the most interesting stocks in biotechnology right now. The company, which bills itself as a biotechnology company and is based in New York, has developed a ...

Management now expects profitability to be achieved in the first half of 2026, later than previously indicated. Otto said, "we now expect the impact of delays in the time necessary to execute the ...

TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF 22ND CENTURY GROUP, INC. (“22ND CENTURY” OR THE “COMPANY”) COMMON STOCK AS OF MARCH 4, 2025. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS ...

The average one-year price target for 22nd Century Group (NasdaqCM:XXII) has been revised to $137.70 / share. This is an increase of 1,400.00% from the prior estimate of $9.18 dated January 11, 2026.

22nd Century announces readiness to support the FDA's proposed standard to reduce nicotine content in cigarettes. The possible regulation passed review by the U.S. Office of Management and Budget on ...